Independent
Tenure on this board
12.3 yrs
Meeting calendar
IDXX · Annual meeting · Tuesday, May 12, 2026
Idexx Laboratories Inc
4 nominees · 6 ballot items.
Election of three Class II directors; Ratification of PwC as auditors; Advisory approval of executive compensation; Amend certificate to declassify the Board; Amend certificate to allow shareholders owning 25% to call special meetings; Shareholder proposal to allow shareholders owning 10% to call special meetings.
Market cap
$45.4B
1Y TSR
+2.6%
Board grade
C
Record date
Mar 16, 2026
Filing
DEF 14A
Meeting concluded · May 12, 2026
Follow how the vote landed and what changed on Idexx Laboratories Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot6
- 1
Election of Directors
ManagementBoard: FORElect three Class II director nominees (Daniel M. Junius, Lawrence D. Kingsley and Sophie V. Vandebroek, PhD) for three-year terms expiring at the 2029 Annual Meeting.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of PricewaterhouseCoopers LLP as IDEXX’s independent registered public accounting firm for 2026.
- 3
Advisory Vote to Approve Executive Compensation
ManagementBoard: FORNon-binding advisory vote to approve the compensation of named executive officers as disclosed in the proxy statement (say-on-pay).
- 4
Amend Certificate of Incorporation to Declassify the Board
ManagementBoard: FORApprove amendments to the Certificate of Incorporation to phase out the classified board structure over a three-year period, resulting in annual director elections beginning in 2029.
- 5
Amend Certificate of Incorporation to Provide Shareholders Owning 25% the Right to Have IDEXX Call a Special Meeting
ManagementBoard: FORApprove amendments to the Certificate of Incorporation to allow shareholders owning at least 25% of outstanding shares continuously for one year to request that the Company call a special meeting, subject to procedures and limitations in the By-Laws.
- 6
Shareholder Proposal to Give Shareholders the Ability to Call for a Special Shareholder Meeting
Shareholder — John CheveddenBoard: AGAINSTShareholder proposal requesting the Board amend governance documents to give shareholders owning 10% of shares the right to call a special meeting, with no ownership holding period.
More detail
The shareholder proposal requests that the Board provide shareholders holding 10% of outstanding shares the right to call special meetings without a holding period. The proponent (John Chevedden) argues this is necessary to prevent Board complacency and cites comparable support at several companies; claims special meetings are rare and online meetings make them feasible. Management opposes the proposal, recommending instead Proposal Five which would grant the right to shareholders meeting a 25% ownership threshold and one-year holding period. Management's rationale emphasizes the operational burden, costs, and risk of minority shareholder coercion under a 10% threshold, points to market practice favoring higher thresholds (25% common among S&P 500 companies), and notes existing governance mechanisms. The Board recommends a vote against the 10% proposal and for Proposal Five.
Director elections
Nominees on the ballot4
Independent
Tenure on this board
9.7 yrs
Also a director at
Polaris Inc (PII)Mirion Technologies Inc (MIR)
Independent
Tenure on this board
13.1 yrs
Also a director at
Revvity Inc (RVTY)
Not independent
Tenure on this board
0.2 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 6.6% | 5,182,507 | $2.9B |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5.0% | 3,910,863 | $2.2B |
| 3 | BlackRock, Inc. | 4.7% | 3,675,297 | $2.1B |
| 4 | STATE STREET CORP | 4.7% | 3,674,185 | $2.1B |
| 5 | Invesco Ltd. | 3.5% | 2,737,276 | $1.5B |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 3.1% | 2,411,983 | $1.4B |
| 7 | BlackRock, Inc. | 2.1% | 1,663,775 | $935M |
| 8 | BAMCO INC /NY/ | 2.1% | 1,633,367 | $918M |
| 9 | Fundsmith LLP | 1.9% | 1,465,786 | $824M |
| 10 | BLAIR WILLIAM CO/IL | 1.2% | 946,336 | $532M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Idexx Laboratories Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Steris PLCSTE
Annual meeting·Jul 31, 2026·$21.6B
Jazz Pharmaceuticals PLCJAZZ
Annual meeting·Jul 23, 2026·$15.2B
Apogee Therapeutics IncAPGE
Special meeting·Aug 11, 2026·$10.1B
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.8B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$4.1B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.6B
Reference
Frequently asked questions
- When is the Idexx Laboratories Inc 2026 annual meeting?
- Idexx Laboratories Inc (IDXX) holds its 2026 annual shareholder meeting on Tuesday, May 12, 2026.
- What is the record date for the Idexx Laboratories Inc 2026 meeting?
- The record date for the Idexx Laboratories Inc 2026 meeting is Monday, March 16, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Idexx Laboratories Inc's 2026 meeting?
- The board is presenting 4 director nominees at the Idexx Laboratories Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Idexx Laboratories Inc 2026 meeting?
- Shareholders will vote on 6 proposals at the Idexx Laboratories Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.